

Fine Foods: acquisition of 100% of Sofar S.p.A. completed

Following the Group's growth strategy, the transaction broadens Fine Foods' industrial capabilities, product-form portfolio, and strengthens its competitive position.

Verdellino (Bergamo, Italy), 12 June 2026 - **Fine Foods & Pharmaceuticals N.T.M. S.p.A.** - an Italian independent Contract Solutions Development & Manufacturing Organization (CSDMO) specialising in the contract development and manufacturing of products for the nutraceutical, pharmaceutical, and cosmetics industries, listed on Euronext STAR Milan (ticker: FF) announces that it has today completed the acquisition of 100% of the share capital of **Sofar S.p.A.** from **Alfasigma S.p.A.**, a global pharmaceutical company headquartered in Italy with more than 75 years of history, after meeting the relevant conditions precedent and under the agreement signed and disclosed to the market on 17 April 2026.

Further to the information previously disclosed, the transaction consideration is €23.4 million, paid today in cash through bank financing. The amount was calculated based on a 100% Enterprise Value of €27 million, adjusted for the net financial position, settlement of intra-group balances and specific contractual adjustments agreed by the parties.

The transaction aligns with Fine Foods' industrial strategy to strengthen and expand its production. The acquisition allows Fine Foods to add expertise and technology for developing and producing liquid and semi-solid pharmaceutical forms, expanding its industrial capabilities.

By completing this transaction, Fine Foods broadens its service portfolio, reinforces its competitive role as a strategic and integrated partner, and enhances its capability to secure new projects and customers.

Following the acquisition of 100% of Sofar S.p.A.'s share capital, operational and organisational continuity will be maintained, while the industrial partnership with Alfasigma S.p.A. will be strengthened. Alfasigma will retain ownership of the products manufactured at the Trezzano Rosa (Milan) facility, and manufacturing and supply activities will continue under a long-term contract agreement with the Fine Foods Group.

For this transaction, Fine Foods received financial advice from KPMG and legal counsel from GA-Alliance. Alfasigma was supported by EY Parthenon which acted as its financial adviser.

You can find the definition of alternative performance indicators in the "Alternative Performance Indicators" section of the Annual Financial Report.

The Company shares regulated information through the authorised 1info storage system managed by Computershare S.p.A. at www.1info.it.

This press release is available on the website www.finefoods.it, in the Investor Relations/Press Releases section.

Fine Foods & Pharmaceuticals N.T.M. S.p.A., listed on Borsa Italiana's Euronext STAR Milan (Ticker: FF) is an Italian independent Contract Solutions Development & Manufacturing Organization (CSDMO) specialising in the contract development and manufacturing of products for the nutraceutical, pharmaceutical and cosmetics industries, with a customer-centric, service-oriented philosophy. Founded in 1984, Fine Foods proved to be a reliable and capable strategic partner for customers in the reference sectors. The company's organisation can provide successful design process and solid, long-term partnerships. The continuous search for excellence is part of the company's business model and includes research and development, innovation, process reliability, product quality, ESG, and sustainable management of the Group's supply chain. Fine Foods is a benefit corporation which relies on certifications and ratings under international standards. These guarantee its sustainability commitment across the business. Fine Foods is a growing and future-oriented company.

Alfasigma is a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered today in Bologna and Milan. The Group's products are distributed in more than 100 markets worldwide. Alfasigma operates offices across major European countries, as well as in the United States, China, and Mexico; production facilities in Italy, Spain, and the United States; and R&D laboratories located in Italy. The company employs approximately 4,000 professionals dedicated to the research, development, production, and distribution of medicinal products. Its portfolio ranges from consumer healthcare products and primary care treatments to specialty and rare disease medications, with key therapeutic areas including gastroenterology, vascular health, and immunology.

For further information:

Fine Foods & Pharmaceuticals N.T.M. S.p.A. Press Office

Tel +39 035 4821382

Investor Relations: ir@finefoods.it

Media Relations: media.relations@finefoods.it